Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA Submission

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA Submission

Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral

August 7, 2015 7:02 AM EDT

Piper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $48.00 (from $39.00), saying with the Pima' NDA filed the next steps may be more challenging.

Analyst Charles Duncan commented, "ACADIA ended 2Q with $271M in cash,... More

Cowen Raises Price Target on Acadia Pharma (ACAD) Following 2Q15

August 7, 2015 6:56 AM EDT

Cowen reiterated an Outperform rating on Acadia Pharmaceuticals (NASDAQ: ACAD), and raised the price target to $50.00 (from $43.00), following 2Q15 results. ACAD reported 2Q15 EPS of $(0.39) vs consensus of $(0.33).

Analyst Ritu Baral commented, "ACAD's 2Q15 call was largely uneventful with ACAD... More